Gold price rebounds after correction

Gold prices have rebounded following a bout of heavy selling as investors cashed in on gold’s bumper rally driven by a weaker dollar.

Gold bugs will be encouraged to see such a swift correction, which was quickly bought into, preventing any major downside in the precious metal.

“Gold has just rebounded from around $3,717/oz after a healthy correction, following a strong rally that pushed prices toward a new high near $3,790/oz,” explained Linh Tran, Market Analyst at XS.com.

“This pullback mainly reflects profit-taking after the extended uptrend and growing investor caution as the balance of U.S. macro data this week tilted toward “moderately positive”: New Home Sales came in at 800K (well above the 650K forecast and higher than the previous 664K), while Q2 GDP was revised up to 3.8%, indicating stronger-than-expected growth. These figures helped strengthen the USD and cooled safe-haven flows, creating near-term resistance for gold, even though Treasury yields only edged up slightly and the geopolitical backdrop remains complex.”

Tran continued to outline that US economic data and PCE holds the key to the next phase of the gold price movement.

“The next focal point is Core PCE—the Fed’s preferred inflation gauge. Inflation alone can exert opposing forces on gold. If PCE eases further, expectations of monetary easing would be reinforced, real yields would trend lower, and in principle this would be supportive for gold. Conversely, if inflation cools while growth remains solid, capital may rotate toward risk assets (equities, credit), reducing safe-haven demand in the short term and putting deeper corrective pressure on gold.

“Should PCE surprise on the upside, a hawkish repricing could push USD and real yields higher, weighing on gold. However, ongoing geopolitical uncertainty and strategic buying interest could limit the downside.”

Gulf Keystone announces restart of Kurdistan crude exports

Gulf Keystone Petroleum has signed agreements with Kurdish and Iraqi governments to restart international crude exports from Kurdistan via the Iraq-Türkiye Pipeline.

Pipeline exports from the Shaikan Field are expected to begin within days.

The restart follows compliance with Iraq’s 2023-2025 Budget Law while preserving Kurdistan’s Production Sharing Contracts. During an interim three-month period, oil companies will receive compensation covering production and transportation costs. Gulf Keystone expects improved realised prices above $30 per barrel, up from $27-28 in local sales.

Iraq’s SOMO will transport crude from Fishkhabour to Ceyhan, with sales at Kirkuk blend prices.

“The restart of Kurdistan crude exports via the Iraq-Türkiye Pipeline is a historic milestone for Gulf Keystone, Kurdistan and Iraq that is expected to unlock significant value for all stakeholders,” said Jon Harris, Gulf Keystone’s Chief Executive Officer.

“A return to international sales prices will be transformative for the Company’s cash flow while we believe the signed agreements with the KRG and FGI, along with the Production Sharing Contracts, will facilitate long term profitable investment in Kurdistan’s oil and gas reserves, of which the Shaikan Field accounts for a significant portion. We are delighted to have reached this successful resolution and are looking forward to the future as we remain focused on driving value for Gulf Keystone shareholders.”

The company continues negotiations with Kurdistan’s government over outstanding receivables from October 2022 to March 2023.

Dunedin Income Growth Investment Trust: Building a resilient portfolio

In the latest manager update video for Dunedin Income Growth Investment Trust, Co-Manager Rebecca Maclean discusses the impact of tariffs on the portfolio, and provides an update on recent performance. Capital at risk.

Dunedin Income Growth Investment Trust : Meet the manager

Ben Ritchie, Co-manager of Dunedin Income Growth Investment Trust, introduces the trust and provides insights into his career in investment management.

FTSE 100 slips amid European selling

The FTSE 100 fell on Thursday amid a Europe-wide equity retreat, and London’s leading index factored in a raft of stocks trading ex-dividend.

“There was a sea of red across European markets as healthcare, real estate, financials and industrial stocks were out of fashion,” said Russ Mould, investment director at AJ Bell. 

“Weakness in names such as HSBC and AstraZeneca would suggest a more cautious tone among investors, but not a complete shift in sentiment.”

London’s leading index was down 0.4% at the time of writing.

There were more severe declines in Europe, as German consumer data continued to show negativity that pointed to a possible slowdown.

“The biggest downside moves were seen in the German DAX and French CAC which were down 0.7% and 0.6% respectively as lunchtime approached. The Swiss National Bank left its key interest rate unchanged at zero, as expected,” explained David Morrison, Senior Market Analyst at Trade Nation.

“The German GfK Consumer Climate survey was also broadly in line with forecasts. It continues to indicate a fair amount of pessimism amongst those surveyed. The index has been stuck deep in negative territory for the last four years.”

The rip-roaring rally in US stocks shows further signs of a pause, and the S&P 500 was heading for a weaker open, albeit a minor one compared to recent gains.

Stocks trading ex-dividend were among the top FTSE 100 fallers on Thursday, with Phoenix Group losing 5%.

There were also more declines for Ashtead and ConvaTec as the pair posted a second session of notable losses.

JD Sports recovered some of yesterday’s losses caused by their interim results as the group began a £100m share buyback programme.

Rio Tinto was the FTSE 100’s top riser with gains of 2%.

AIM movers: Arecor Therapeutics collaboration and ex-dividends

2

Late yesterday, Nativo Resources (LON: NTVO) announced it is raising £400,000 at 0.45p/share. Each share comes with a warrant exercisable at 0.45p/share. The funds will be used to progress the Tesoro gold concession in Peru. The share price recovered 22.4% to 0.55p.

Arecor Therapeutics (LON: AREC) announced a co-development agreement with US insulin device company Sequel MedTech for AT278, which enables longer-wear and miniaturised automated insulin delivery systems. Up to $1.3m will be committed to fund development work for a phase 2 trial. Arecor Therapeutics has generated funding by selling royalty right and milestone and technology fees for two other products. The initial payment is $7m with $4m more if milestones are achieved. Cash was £1.9m at the end of June 2025. The cash should last until the first half of 2027. The share price increased 19.3% to 86.5p.

Daniel J Holliday has sold his 4.2% stake in Light Science Technologies (LON: LST). The share price rose 14.1% to 4.05p.

Nevada-focused exploration company Great Western Mining (LON: GWMO) had €1.24m in cash at the end of June 2025. There should be further news upcoming from drilling at West Huntoon, with more drilling planned to validate surface anomalies, and maiden results from gold drilling at the Olympic project. Initial tungsten exploration has commenced. There are funding discussions for to commission the Western Milling tailings mill and seeking joint venture partners for copper projects. The share price improved 19.2% to 1.55p.

FALLERS

Proteome Sciences (LON: PRM) reported a reduction in interim revenues from £2.22m to £1.86m due to lower reagent sales and royalties. Uncertainty in the US life sciences market has hit demand and this will continue into the second half. The share price dived 44.5% to 1.755p.

Bradda Head Lithium (LON: BHL) has entered a short-term loan facility of $500,000 with Galloway. This can be drawn down at the request of the company, and it lasts for one year. The share price fell 26.6% to 1.05p.

Trading has been slower than expected at electricals retailer Marks Electrical (LON: MRK) with a weak second quarter. The operational gearing means that profitability will be hit. Canaccord Genuity expects a small loss this year before a recovery to £900,000 next year. There will be a decision on the dividend at a later date. The share price slipped 21% to 49p.

Medical device developer Polarean Imaging (LON: POLX) reported a 45% drop in interim revenues to $600,000, which was well below expectations of $1.5m. There was a lack of polariser orders from US hospitals and research organisations. Full year revenues guidance has been cut and Stifel reduced its forecast from $5.4m to $2.5m. There are $1.2m of orders for the second half. Revenues could double in 2026. Cash could reduce to $3.5m at the end of 2025. The share price declined 17.4% to 0.475p.

Ex-dividends

Alumasc (LON: ALU) is paying a dividend of 7.6p/share and the share price fell 7.5p to 342.5p.

Advanced Medical Solutions (LON: AMS) is paying a dividend of 0.85p/share and the share price slipped 7.25p to 215.75p.

Central Asia Metals (LON: CAML) is paying an interim dividend of 4.5p/share and the share price edged down 2.8p to 153p.

Duke Capital (LON: DUKE) is paying a dividend of 0.7p/share and the share price declined 0.75p to 29.25p.

Eleco (LON: ELCO) is paying an interim dividend of 0.35p/share and the share price is unchanged at 148.5p.

Fevertree Drinks (LON: FEVR) is paying an interim dividend of 5.97p/share and the share price is 12p lower at 881p.

FIH Group (LON: FIH) is paying a dividend of 75.5p/share and the share price declined 50p to 260p.

Fletcher King (LON: FLK) is paying a final dividend of 2.25p/share and the share price decreased 2p to 39.5p.

Fintel (LON: FNTL) is paying an interim dividend of 1.3p/share and the share price fell 1.5p to 237.5p.

FRP Advisory (LON: FRP) is paying a dividend of 1p/share and the share price moved down 1.5p to 147p.

Hargreaves Services (LON: HSP) is paying a final dividend of 18.5p/share and the share price dipped 17p to 747p.

Ingenta (LON: ING) is paying an interim dividend of 1.75p/share and the share price fell 1.25p to 72.25p.

Personal Group Holdings (LON: LGH) is paying an interim dividend of 8.2p/share and the share price dipped 18p to 314p.

System1 (LON: SYS1) is paying a dividend of 11p/share and the share price fell 15p to 255p.

Wynnstay Group (LON: WYN) is paying an interim dividend of 5.7p/share and the share price is unchanged at 370p.

Guident IPO, AI investments, and further NAV growth with Tekcapital

The UK Investor Magazine was delighted to welcome Dr Clifford Gross, CEO of Tekcapital, to delve into the technology investment company’s latest results and upcoming Guident IPO.

We begin by reviewing Tekcapital’s half-year results, which continue to demonstrate net asset value growth driven by the appreciation of its portfolio companies.

Having filed its S-1 publicly with the SEC, Tekcapital portfolio company Guident is on the verge of its NASDAQ IPO, which promises to provide further uplift to TEK’s portfolio. We discuss the investment case and ask the question about a potential valuation.

We conclude by examining plans for the portfolio following the Guident IPO and where Tekcapital sees opportunities for its next investments.

Mitchell’s & Butlers shares sink with costs set to rise

Mitchell’s & Butlers shares sank on the warning of cost inflation on Thursday despite the pub group posting fairly decent sales growth.

The group has produced reasonable sales growth throughout the 51-week period ending September 20, 2025, achieving 4.2% like-for-like sales growth year-to-date and 3.9% total sales growth.

Food sales grew 4.1% and drink sales rose 4.0% for the period.

However, the warning that costs would rise at 6%, outstripping recent sales growth, put the firm on course for margin compression. Investors baulked, and shares were 7% on Thursday.

“Harvester and All Bar One proprietor, Mitchell’s & Butlers has served up a reassuring full-year trading update. Fourth quarter sales growth has slowed, reflecting some hesitation among pub and restaurant goers in the broader market, but the group has extended its track record of outperforming the competition,” explained Derren Nathan, head of equity research, Hargreaves Lansdown.

“It’s set to deliver operating profit growth of around 5% to £328 million, an outcome worth raising a glass to, given the additional cost burden brought about by higher National Insurance contributions and the increase in the National Living Wage. There’s around another £130 million of cost inflation expected next year, which could dampen spirits.”

Nathan continued to explain that while there were some positives for Mitchell’s & Butlers, the challenges related to the UK consumer and the current valuation of the stock made the company an unattractive proposition.

“The group’s diverse brand portfolio, well-invested estate, and focus on efficiency, leaves it well placed to mitigate this pressure, while outgrowing the market. But the shares have more than doubled over the last three years and the valuation broadly reflects recent operational improvements. With consumer sentiment fragile, and the potential for a further tax grab in the November budget, there’s no obvious catalyst for near-term appreciation.”

Halma shares gain on positive trading update

Halma shares rose on Thursday after the group upgraded its revenue growth guidance after stronger-than-expected performance in the first half of its financial year.

The company now expects low double-digit organic growth for the full year, up from previous guidance of upper single digits. A driving force behind the upgrade was the strength in its photonics business within the Environmental & Analysis division.

Halma shares were up over 1% at the time of writing.

Order intake has outpaced both current revenue and last year’s comparable period, providing momentum for continued expansion. The group maintains its profit margin guidance of modestly above the midpoint of its 19-23% target range.

Investors should be pleased with the update, and the gains for shares would likley be stronger if Halma shares were not already up 25% year to date.

Acquisition Activity Continues

Halma has grown through acquisitions over the years and completed two acquisitions during the period. The larger deal saw it purchase Brownline, a specialist in gyroscopic locating systems for underground drilling, for €150m in August. It also acquired cryogenic therapy company Nu Perspectives for £1.5m as an add-on to its healthcare business.

The group disposed of AAI for approximately £10m whilst maintaining what it describes as a “healthy acquisition pipeline” for future deals.

Currency headwinds from sterling’s strength are expected to continue impacting results through the second half. Despite this, the company’s cash generation remains robust, supporting both organic investment and acquisitions.

AIM movers: Nigel Wray doubles stake in Sosandar and Fiske under FCA restrictions

5

Nigel Wray has increased his shareholding in women’s clothing retailer Sosandar (LON: SOS) from 2.06% to 4.07%. Lombard Odier trimmed its stake from 5.01% to 4.67%. The share price increased 10% to 5.5p.

First Property Group (LON: FPO) expects further profit improvement this year. At the AGM, the company said that contracts have been exchanged for the sale of two buildings. The sale proceeds are £4.1m and the gain should be around £1.2m. Funds under management wee steady at £220m at the end of August 2025. Interim results will be released on 27 November. The share price recovered 9.84% to 16.75p.

Revolution Beauty (LON: REVB) non-executive director Rachel Horsefield has decided not to seek re-election. The share price improved 8.81% to 3.025p.

Artemis Resources (LON: ARV) is testing three shallow gold targets at Titan in the Karratha gold project. There will be 1,600 metres of drilling. There are also plans for drilling at the Carlow resource. The share price rose 7.14% to 0.375p.

FALLERS

Pharmacogenetic testing company Genedrive (LON: GDR) has raised £3.2m at 0.2p/share and there could be an additional £100,000 forthcoming. A retail offer of up to £300,000 has been launched and closes on 26 September. Each share comes with one warrant exercisable at 0.4p each. The cash will fund commercialisation of the company’s tests and a FDA 510(k) submission for a test that identifies stroke and cardiovascular patients unlikely to respond to medication early next year. The share price dived 53.3% to 0.245p.

Broker Fiske (LON: FKE) has agreed a Voluntary Requirement (VREQ) with the FCA following a review of the company’s systems and controls in the investment management activities. There are no restrictions elating to existing clients, but Fiske is restricted from taking on new clients. Fiske can still pay a final dividend. Full year revenues are estimated to be 6% higher at £7.9m. Pre-tax profit is 43% ahead at £1.4m. Cash was more than £6.5m at the end of June 2025. This is after additional costs relating to the VREQ. The share price slipped 22.6% to 60p.

Helium One Global (LON: HE1) says investors that advanced £10m in August are converting £1.65m into shares at 0.235p each. The share price fell 13.5% to 0.275p.

Pacsco Ltd (LON: PACS), which was known as Agriterra, will not publish its accounts for the year to March 2025 until October. This is due to the recent disposal of operations in Mozambique. This means trading in the shares will be suspended on 1 October and lifted when the accounts are published. The share price decreased 13.7% to 0.43p.

Digital services provider Made Tech Group (LON: MTEC) increased full year revenues by one-fifth to £46.4m with the growth accelerating in the second half. Pre-tax profit rebounded from £1.4m to £2.9m. The order book is worth £92.2m. There has been a strong start to the new financial year and a pre-tax profit of £3.2m is forecast. The share price had more than doubled over the past year, but it dipped 12.4% to 35.5p.